Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Department of Animal Resource & Science, Dankook University, Cheonan, Korea.
Korean J Gastroenterol. 2020 Mar 25;75(3):141-146. doi: 10.4166/kjg.2020.75.3.141.
BACKGROUND/AIMS: Dysbiosis is an important factor in the pathogenesis of irritable bowel syndrome (IBS). Several studies have reported promising results using probiotics for the treatment of IBS. This study evaluated the efficacy of novel probiotics isolated from Kimchi, a Korean fermented food, and the feces of healthy Vietnamese people in a murine model of IBS.
DK121 was isolated from Kimchi, and V4 and V7 were isolated from the feces of healthy Vietnamese people residing in Korea. Forty rats were allocated to receive one of the study strains, a mixture of the strains, or the vehicle. After 5 days of administration, the rats were restrained in a cage to induce IBS. The effects of the probiotics on IBS were analyzed by evaluating the stool weights and stool consistency scores.
The primary outcome was analyzed upon the completion of a three-week experiment. The rats in the V7 group showed lower stool weights than those in the control group at week 2 (median: 1.10 [V7] vs. 2.35 [control], p=0.04, Mann-Whitney U-test) and week 3 (median: 1.10 [V7] vs. 2.80 [control], p=0.017). The rats in the DK121 (median: 2.00, p=0.007), V7 (median: 2.00, p=0.004), and mixture (median: 1.50, p=0.001) groups showed better stool consistency scores at week 2 than the control group (median: 3.00).
The novel probiotics have beneficial effects on defecation in a murine model of IBS. Human studies confirming the efficacy are warranted.
背景/目的：肠道菌群失调是肠易激综合征（IBS）发病机制中的一个重要因素。几项研究报告了使用益生菌治疗 IBS 的有希望的结果。本研究评估了从韩国发酵食品泡菜中分离的新型益生菌和从居住在韩国的健康越南人粪便中分离的益生菌 V4 和 V7 在 IBS 小鼠模型中的疗效。
从泡菜中分离出 DK121，从居住在韩国的健康越南人粪便中分离出 V4 和 V7。将 40 只大鼠分为接受研究菌株、菌株混合物或载体的一组。给药 5 天后，将大鼠束缚在笼子中以诱导 IBS。通过评估粪便重量和粪便稠度评分来分析益生菌对 IBS 的影响。
主要结局在为期三周的实验完成后进行分析。在第 2 周（中位数：1.10 [V7] vs. 2.35 [对照]，p=0.04，Mann-Whitney U 检验）和第 3 周（中位数：1.10 [V7] vs. 2.80 [对照]，p=0.017），V7 组的大鼠粪便重量低于对照组。在第 2 周（中位数：DK121 为 2.00，p=0.007；V7 为 2.00，p=0.004；混合物为 1.50，p=0.001），DK121、V7 和混合物组的大鼠粪便稠度评分优于对照组（中位数：3.00）。
新型益生菌对 IBS 小鼠模型的排便有有益作用。需要进行人类研究以确认其疗效。
